Compare Recursion Pharmaceuticals Inc (RXRX) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs SYSCO Corporation — how do they compare? Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B), while SYSCO Corporation trades at $83.87 (market cap $40.32B). The key difference: SYSCO Corporation is far larger — about 22.3× Recursion Pharmaceuticals Inc's market cap, and SYSCO Corporation pays a 2.61% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SYY | |
|---|---|---|
Market Cap | $1.81B | $40.32B |
Sector | Health | Consumer Staples |
52-Week High | $6.79 | $91.16 |
52-Week Low | $2.84 | $69.30 |
Enterprise Value | $1.33B | $53.50B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
SYY trades at $83.87, down 0.5% for the day, with a neutral technical signal and bullish moving averages. The company reported Q4 2026 EPS of $1.53, beating estimates, and revenue of $81.37B in 2025, with steady growth. Analyst consensus is a Buy with a $88.25 price target, and recent news highlights strong quarterly results and efficiency initiatives.
Outlook is positive due to earnings beats and growth initiatives, but risks include margin pressure and debt levels. The stock offers value with a P/E of 23.02 and P/S of 0.48, supported by institutional optimism, though macroeconomic uncertainty remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
